Terms: = Lymphoma AND CD52, CDW52, EDDM5
223 results:
1. Maintenance therapy for chronic lymphocytic leukaemia.
Lee CH; Wu YY; Huang TC; Lin C; Zou YF; Cheng JC; Chen PH; Jhou HJ; Ho CL
Cochrane Database Syst Rev; 2024 Jan; 1(1):CD013474. PubMed ID: 38174814
[TBL] [Abstract] [Full Text] [Related]
2. Histopathological Markers for Target Therapies in Primary Cutaneous lymphomas.
Sonego B; Ibatici A; Rivoli G; Angelucci E; Sola S; Massone C
Cells; 2023 Nov; 12(22):. PubMed ID: 37998391
[TBL] [Abstract] [Full Text] [Related]
3. Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia.
Chiesa R; Georgiadis C; Syed F; Zhan H; Etuk A; Gkazi SA; Preece R; Ottaviano G; Braybrook T; Chu J; Kubat A; Adams S; Thomas R; Gilmour K; O'Connor D; Vora A; Qasim W;
N Engl J Med; 2023 Sep; 389(10):899-910. PubMed ID: 37314354
[TBL] [Abstract] [Full Text] [Related]
4. Heterogeneity of B cell lymphopoiesis in patients with premalignant and active myeloma.
Jakubikova J; Cholujova D; Beke G; Hideshima T; Klucar L; Leiba M; Jamroziak K; Richardson PG; Kastritis E; Dorfman DM; Anderson KC
JCI Insight; 2023 Feb; 8(3):. PubMed ID: 36752202
[TBL] [Abstract] [Full Text] [Related]
5. Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia.
Ottaviano G; Georgiadis C; Gkazi SA; Syed F; Zhan H; Etuk A; Preece R; Chu J; Kubat A; Adams S; Veys P; Vora A; Rao K; Qasim W;
Sci Transl Med; 2022 Oct; 14(668):eabq3010. PubMed ID: 36288281
[TBL] [Abstract] [Full Text] [Related]
6. [scRNA-sequencing uncovers metabolism and cd52 as new targets in ibrutinib-surviving mantle cell lymphoma cells].
Fuhr V; Vafadarnejad E; Dietrich O; Arampatzi P; Riedel A; Saliba AE; Rosenwald A; Rauert-Wunderlich H
Pathologie (Heidelb); 2022 Aug; 43(Suppl 1):31-35. PubMed ID: 36222922
[TBL] [Abstract] [Full Text] [Related]
7. Monoclonal antibodies for the treatment of acute lymphocytic leukemia: A literature review.
Pourmontaseri H; Habibzadeh N; Entezari S; Samadian F; Kiyani S; Taheri M; Ahmadi A; Fallahi MS; Sheikhzadeh F; Ansari A; Tamimi A; Deravi N
Hum Antibodies; 2022; 30(3):117-130. PubMed ID: 35662114
[TBL] [Abstract] [Full Text] [Related]
8. Clinical Guidelines and New Molecular Targets for Cutaneous lymphomas.
Sugaya M
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681738
[TBL] [Abstract] [Full Text] [Related]
9. Time-Resolved scRNA-Seq Tracks the Adaptation of a Sensitive MCL Cell Line to Ibrutinib Treatment.
Fuhr V; Vafadarnejad E; Dietrich O; Arampatzi P; Riedel A; Saliba AE; Rosenwald A; Rauert-Wunderlich H
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33668876
[TBL] [Abstract] [Full Text] [Related]
10. CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia.
Hu Y; Zhou Y; Zhang M; Ge W; Li Y; Yang L; Wei G; Han L; Wang H; Yu S; Chen Y; Wang Y; He X; Zhang X; Gao M; Yang J; Li X; Ren J; Huang H
Clin Cancer Res; 2021 May; 27(10):2764-2772. PubMed ID: 33627493
[TBL] [Abstract] [Full Text] [Related]
11. IL-15 in the Combination Immunotherapy of Cancer.
Waldmann TA; Dubois S; Miljkovic MD; Conlon KC
Front Immunol; 2020; 11():868. PubMed ID: 32508818
[TBL] [Abstract] [Full Text] [Related]
12. Patterns of Late Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with T-Cell Prolymphocytic Leukemia.
Shumilov E; Hasenkamp J; Szuszies CJ; Koch R; Wulf GG
Acta Haematol; 2021; 144(1):105-110. PubMed ID: 32259827
[TBL] [Abstract] [Full Text] [Related]
13. Advances and Perspectives in the Treatment of T-PLL.
Braun T; von Jan J; Wahnschaffe L; Herling M
Curr Hematol Malig Rep; 2020 Apr; 15(2):113-124. PubMed ID: 32034661
[TBL] [Abstract] [Full Text] [Related]
14. Characterization of an Anti-CD5 Directed CAR T-Cell against T-Cell Malignancies.
Wada M; Zhang H; Fang L; Feng J; Tse CO; Zhang W; Chen Q; Sha S; Cao Y; Chen KH; Pinz KG; Chen X; Fan XX; Jiang X; Ma Y
Stem Cell Rev Rep; 2020 Apr; 16(2):369-384. PubMed ID: 32008159
[TBL] [Abstract] [Full Text] [Related]
15. Acute myocardial infarction associated with initial alemtuzumab infusion cycle in relapsing-remitting multiple sclerosis.
Romba MC; Newsome SD; McArthur JC
Mult Scler Relat Disord; 2019 Sep; 34():100-102. PubMed ID: 31252364
[TBL] [Abstract] [Full Text] [Related]
16. Existing and Emerging Therapies for Cutaneous T-Cell lymphoma.
Van-de-Velde V; Zhou Y
J Cutan Med Surg; 2019; 23(3):319-327. PubMed ID: 30943788
[TBL] [Abstract] [Full Text] [Related]
17. Single-cell RNA-Seq of follicular lymphoma reveals malignant B-cell types and coexpression of T-cell immune checkpoints.
Andor N; Simonds EF; Czerwinski DK; Chen J; Grimes SM; Wood-Bouwens C; Zheng GXY; Kubit MA; Greer S; Weiss WA; Levy R; Ji HP
Blood; 2019 Mar; 133(10):1119-1129. PubMed ID: 30591526
[TBL] [Abstract] [Full Text] [Related]
18. Loss of the GPI-anchor in B-lymphoblastic leukemia by epigenetic downregulation of PIGH expression.
Loeff FC; Rijs K; van Egmond EHM; Zoutman WH; Qiao X; Kroes WGM; Veld SAJ; Griffioen M; Vermeer MH; Neefjes J; Frederik Falkenburg JH; Halkes CJM; Jedema I
Am J Hematol; 2019 Jan; 94(1):93-102. PubMed ID: 30370942
[TBL] [Abstract] [Full Text] [Related]
19. An IgG1-like bispecific antibody targeting cd52 and CD20 for the treatment of B-cell malignancies.
Qi J; Chen SS; Chiorazzi N; Rader C
Methods; 2019 Feb; 154():70-76. PubMed ID: 30145356
[TBL] [Abstract] [Full Text] [Related]
20. Assessment of cd52 expression in "double-hit" and "double-expressor" lymphomas: Implications for clinical trial eligibility.
Craig JW; Mina MJ; Crombie JL; LaCasce AS; Weinstock DM; Pinkus GS; Pozdnyakova O
PLoS One; 2018; 13(7):e0199708. PubMed ID: 30020951
[TBL] [Abstract] [Full Text] [Related]
[Next]